The journey from clinical trials to market approval is rigorous, but the promising results from retatrutide have undoubtedly generated significant anticipation
Inject the air into the vial
Gastrointestinal side effects: GLP-1-based agents, including retatrutide, commonly cause nausea, vomiting, diarrhoea, and reduced appetite, partly through slowing of gastric emptying
It supports muscle relaxation, nerve function, bone health, blood sugar regulation, and sleep quality
Providers may decline treatment for any clinical reason
Trial participation offers free medication and close medical monitoring, but comes with significant commitments including frequent clinic visits over 48 to 72 weeks and the possibility of randomization to placebo